| Revision as of 16:33, 9 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 468946478 of page Methyl_aminolevulinate for the Chem/Drugbox validation project (updated: 'DrugBank', 'ChEMBL'). |
Latest revision as of 14:51, 10 June 2024 edit Marbletan (talk | contribs)Extended confirmed users5,418 edits no longer a stub |
| Line 1: |
Line 1: |
|
|
{{short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 462250156 |
|
| verifiedrevid = 470457959 |
|
| IUPAC_name = methyl 5-amino-4-oxo-pentanoate |
|
| IUPAC_name = Methyl 5-amino-4-oxopentanoate |
|
| image = Methyl aminolevulinate.svg |
|
| image = Methyl aminolevulinate.svg |
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = |
| Line 17: |
Line 17: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
|
| bioavailability = |
|
| bioavailability = |
| Line 24: |
Line 23: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
| ⚫ |
| CASNo_Ref = {{cascite|correct|CAS}} |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 33320-16-0 |
|
| CAS_number = 33320-16-0 |
|
⚫ |
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 585NM85KYM |
|
| ATC_prefix = L01 |
|
| ATC_prefix = L01 |
|
| ATC_suffix = XD03 |
|
| ATC_suffix = XD03 |
|
| ATC_supplemental = |
|
| ATC_supplemental = |
|
| PubChem = 16052023 |
|
| PubChem = 157922 |
|
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = DB00992 |
|
| DrugBank = DB00992 |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID = 13180320 |
|
| ChemSpiderID = 13180320 |
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
| ChEMBL = <!-- blanked - oldvalue: 1096562 --> |
|
| ChEMBL = 1096562 |
|
|
<!--Chemical data--> |
|
| C=6 | H=11 | N=1 | O=3 |
|
| C=6 | H=11 | N=1 | O=3 |
|
| molecular_weight = 145.156 g/mol |
|
|
| smiles = O=C(CC(N)C(=O)OC)C |
|
| smiles = O=C(CC(N)C(=O)OC)C |
|
| InChI = 1/C6H11NO3/c1-4(8)3-5(7)6(9)10-2/h5H,3,7H2,1-2H3 |
|
|
| InChIKey = FLQHIIVXMKXKFT-UHFFFAOYAN |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C6H11NO3/c1-4(8)3-5(7)6(9)10-2/h5H,3,7H2,1-2H3 |
|
| StdInChI = 1S/C6H11NO3/c1-4(8)3-5(7)6(9)10-2/h5H,3,7H2,1-2H3 |
| Line 49: |
Line 46: |
|
| StdInChIKey = FLQHIIVXMKXKFT-UHFFFAOYSA-N |
|
| StdInChIKey = FLQHIIVXMKXKFT-UHFFFAOYSA-N |
|
}} |
|
}} |
|
|
|
|
|
'''Methyl aminolevulinate''' (MAL) is a drug used as a ] in ]. It is a ] that is metabolized to ]. It is marketed as '''Metvix'''. |
|
|
|
|
|
Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser. |
|
|
|
|
|
Metvix is developed by ] and ] has bought all rights to Metvix.<ref>{{cite web|url=http://photocure.com/NEWS/newcontainer/Photocure-divests-Metvix-to-Galderma-for-EUR-51-million/ |title= Photocure Divests Metvix to Galderma for EUR 51 Million |access-date=2010-09-10 |url-status=dead |archive-url=https://web.archive.org/web/20110207120321/http://photocure.com/NEWS/newcontainer/Photocure-divests-Metvix-to-Galderma-for-EUR-51-million/ |archive-date=2011-02-07 }}</ref> |
|
|
|
|
|
==Approvals and indications== |
|
|
] with Metvix one week after exposure. Patient has light skin and blue eyes.]] |
|
|
Methyl aminolevulinate is approved in New Zealand for treatment of ].<ref>{{cite web | vauthors = Ngan V | date = 2003 | url = http://dermnetnz.org/procedures/metvix-pdt.html | title = Methyl aminolevulinate photodynamic therapy (MAL PDT) | work = DermNet NZ }}</ref> |
|
|
|
|
|
It is now approved in many countries and has been used to treat non-melanoma ] (including ]).<ref>{{cite web | title = New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment | url = https://www.eurekalert.org/pub_releases/2006-01/shi-n5y013106.php | date = 2006 | work = EurekAlert! }}</ref> |
|
|
|
|
|
It has some advantages over ].<ref name="pmid19682322">{{cite journal | vauthors = O'Connor AE, Gallagher WM, Byrne AT | title = Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy | journal = Photochemistry and Photobiology | volume = 85 | issue = 5 | pages = 1053–74 | date = 2009 | pmid = 19682322 | doi = 10.1111/j.1751-1097.2009.00585.x | s2cid = 205950773 | doi-access = free }}</ref> |
|
|
|
|
|
It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. <ref>{{cite web | title = Concerns raised over ALA skin cancer cream as patients recount 'horrendous' pain | url = http://www.abc.net.au/news/2013-11-16/concerns-raised-over-side-effects-of-skin-cancer-cream/5096496 | date = 16 November 2013 | publisher = Australian Broadcasting Corporation }}</ref> |
|
|
|
|
|
==References== |
|
|
{{Reflist}} |
|
|
|
|
|
{{Chemotherapeutic agents}} |
|
|
|
|
|
{{DEFAULTSORT:Methyl Aminolevulinate}} |
|
|
] |
|
|
] |
|
|
] |
|
|
] |